Revolutionary Peripulse System Approved for Nerve Regeneration
Epineuron has achieved a significant milestone with the approval of its PeriPulse™ system by Health Canada. This innovative nerve...
Epineuron has achieved a significant milestone with the approval of its PeriPulse™ system by Health Canada. This innovative nerve...
In a Phase 1 clinical trial, Metsera’s MET-097 exhibited promising weight loss outcomes, supporting its potential for once-monthly dosing....
LEO Pharma presented data at the 33rd European Academy of Dermatology and Venereology (EADV) Congress on the effectiveness and...
City of Hope, a leading cancer research and treatment institution, has received a $20 million donation from philanthropists Norman...
Genialis, a leader in RNA biomarker development, has announced the launch of Genialis krasID, a groundbreaking biomarker capable of...
Pfizer has voluntarily withdrawn OXBRYTA (voxelotor) from all markets due to an imbalance in vaso-occlusive crises and fatal events...
Merck’s Phase 3 KEYFORM-007 trial tested the efficacy of a fixed-dose combination of favezelimab and pembrolizumab in treating PD-L1-positive...
Japan’s Ministry of Health has approved new indications for KEYTRUDA (pembrolizumab) in treating certain lung and urothelial cancers. KEYTRUDA,...
A groundbreaking medical study, the SuperSaturated Oxygen Comprehensive Observational REgistry (SSCORE), has commenced with enrolling its first patient. This...
TriSalus Life Sciences‘ Pressure Enabled Drug Delivery (PEDD) method enhances the delivery of glass microspheres into liver tumors in...